Savara Inc (NASDAQ:SVRA) was the recipient of some unusual options trading on Tuesday. Investors purchased 2,968 call options on the company. This is an increase of 750% compared to the typical volume of 349 call options.
In other Savara news, CEO Matthew Pauls purchased 28,700 shares of the stock in a transaction that occurred on Monday, February 22nd. The stock was purchased at an average cost of $1.74 per share, with a total value of $49,938.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.77% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Sofinnova Investments Inc. acquired a new stake in shares of Savara during the third quarter worth $409,000. Bank of America Corp DE lifted its holdings in shares of Savara by 48.3% during the second quarter. Bank of America Corp DE now owns 20,603 shares of the company’s stock worth $51,000 after purchasing an additional 6,708 shares during the period. Metropolitan Life Insurance Co NY acquired a new stake in shares of Savara during the first quarter worth $83,000. JPMorgan Chase & Co. lifted its holdings in shares of Savara by 698.8% during the fourth quarter. JPMorgan Chase & Co. now owns 143,729 shares of the company’s stock worth $166,000 after purchasing an additional 125,737 shares during the period. Finally, Rhumbline Advisers lifted its holdings in shares of Savara by 16.7% during the fourth quarter. Rhumbline Advisers now owns 70,848 shares of the company’s stock worth $81,000 after purchasing an additional 10,135 shares during the period. 40.66% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have recently weighed in on the company. Evercore ISI assumed coverage on Savara in a report on Monday, November 23rd. They issued an “outperform” rating for the company. Zacks Investment Research downgraded Savara from a “buy” rating to a “hold” rating in a report on Wednesday, November 4th. Finally, HC Wainwright decreased their price objective on Savara from $6.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, December 15th.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Read More: Equal Weight Rating
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.